Comparison of Neoadjuvant and Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer

被引:14
作者
Macleod, Liam C. [1 ,2 ]
Fam, Mina M. [3 ]
Yabes, Jonathan G. [4 ]
Hale, Nathan E. [5 ]
Turner, Robert M., II [1 ]
Lopa, Samia H. [4 ]
Gingrich, Jeffrey R. [6 ]
Borza, Tudor [7 ]
Skolarus, Ted A. [8 ,9 ,10 ]
Davies, Benjamin J. [1 ]
Jacobs, Bruce L. [1 ]
机构
[1] Univ Pittsburgh, Dept Urol, Med Ctr, Pittsburgh, PA 15232 USA
[2] Asante Rogue Reg Med Ctr, Dept Urol, Medford, OR USA
[3] Jersey Shore Univ, Dept Urol, Med Ctr, Neptune, NJ USA
[4] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15232 USA
[5] Charleston Area Med Ctr, Dept Urol, Charleston, WV USA
[6] Duke Univ, Dept Surg, Div Urol, Durham, NC USA
[7] Univ Wisconsin, Dept Urol, Madison, WI USA
[8] Univ Michigan, Dept Urol, Div Oncol, Ann Arbor, MI 48109 USA
[9] Univ Michigan, Dept Urol, Dow Div Urol Hlth Serv Res, Ann Arbor, MI 48109 USA
[10] VA Ann Arbor Healthcare Syst, VA Hlth Serv Res & Dev, Ctr Clin Management Res, Ann Arbor, MI USA
关键词
Drug therapy; Health services research; Medicare; SEER program; Urinary bladder neoplasms; PERIOPERATIVE CHEMOTHERAPY; CYSTECTOMY; METHOTREXATE; VINBLASTINE; CISPLATIN;
D O I
10.1016/j.clgc.2019.12.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Current guidelines recommend neoadjuvant chemotherapy for patients planning cystectomy for muscle-invasive bladder cancer. We compare outcomes among 676 patients having neoadjuvant chemotherapy with 666 having adjuvant chemotherapy using inverse probability weighting to construct multivariable survival models. There were significant baseline differences in the cohorts selected for each approach, suggesting that in the real-world setting, providers may struggle balancing level 1 evidence with patient factors impacting chemotherapy eligibility. However, after adjustment for selection bias, neoadjuvant timing was associated with a modest, but significant, survival benefit in healthier, younger patients. Background: We use observational methods to compare impact of perioperative chemotherapy timing (ie, neoadjuvant and adjuvant) on overall survival (OS) in muscle-invasive bladder cancer because there is no head-to-head randomized trial, and patient factors may influence decision-making. Patients and Methods: Using Surveillance, Epidemiology, and End Results-Medicare data, we identified patients receiving cystectomy for muscle-invasive bladder cancer diagnosed between 2004 and 2013. Patients were classified as receiving neoadjuvant or adjuvant chemotherapy. Propensity of receiving neoadjuvant chemotherapy was determined using gradient boosted models. Inverse probability of treatment weighted survival curves were adjusted for 13 demographic, socioeconomic, temporal, and oncologic covariates. Results: We identified 1342 patients who received neoadjuvant (n = 676) or adjuvant chemotherapy (n = 666) with a median follow-up of 23 months (interquartile range, 9-55 months). Inverse probability of treatment weighted adjustment allows comparison of the groups head-to-head as well as counterfactual scenarios (eg, effect if those getting one treatment were to receive the other). The average treatment effect (ie, "head-to-head" comparison) of adjuvant compared with neoadjuvant on OS was not significant (hazard ratio, 1.14; 95% confidence interval, 0.99-1.31). However, the average treatment effect of the treated (ie, the effect if the neoadjuvant patients were to receive adjuvant instead) was associated with a 33% increase in risk of mortality if they were given adjuvant therapy instead (hazard ratio, 1.33; 95% confidence interval, 1.12-1.57). Conclusion: Significant treatment selection bias was noted in peri-cystectomy timing, which limits the ability to discriminate differential efficacy of these 2 approaches with observational data. However, patients with higher propensity to receive neoadjuvant therapy were predicted to have increased OS with approach, in keeping with existing paradigms from trial data. (C) 2019 Published by Elsevier Inc.
引用
收藏
页码:201 / +
页数:11
相关论文
共 30 条
[1]  
[Anonymous], 1999, Lancet, V354, P533
[2]   Adjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis of individual patient data [J].
Bono, AV ;
Goebell, PJ ;
Groshen, S ;
Lehmann, J ;
Studer, U ;
Torti, FM ;
Abol-Enein, H ;
Bassi, P ;
Boyer, M ;
Coppin, CML ;
Cortesi, E ;
Hall, RR ;
Horwich, A ;
Malmström, PU ;
Martínez-Piñeiro, JA ;
Sengelov, L ;
Sherif, A ;
Wallace, DMA ;
Clarke, NW ;
Roberts, JT ;
Sylvester, R ;
Parmar, MKB ;
Stewart, LA ;
Tierney, JF ;
Vale, CL .
EUROPEAN UROLOGY, 2005, 48 (02) :189-201
[3]   Perioperative chemotherapy for bladder cancer in the general population: Are practice patterns finally changing? [J].
Booth, Christopher M. ;
Karim, Safiya ;
Brennan, Kelly ;
Siemens, David Robert ;
Peng, Yingwei ;
Mackillop, William J. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (03) :89.e13-89.e20
[4]  
Cohen J., 1988, Journal Of The American Statistical Association, DOI [DOI 10.2307/2290095, 10.4324/9780203771587, DOI 10.4324/9780203771587]
[5]  
de Wreede LC, 2011, J STAT SOFTW, V38, P1
[6]   Treatment of Muscle Invasive Bladder Cancer: Evidence From the National Cancer Database, 2003 to 2007 [J].
Fedeli, Ugo ;
Fedewa, Stacey A. ;
Ward, Elizabeth M. .
JOURNAL OF UROLOGY, 2011, 185 (01) :72-78
[7]   A proportional hazards model for the subdistribution of a competing risk [J].
Fine, JP ;
Gray, RJ .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) :496-509
[8]  
Fradet Yves, 2006, Can J Urol, V13 Suppl 3, P37
[9]   Mortality Increases When Radical Cystectomy Is Delayed More Than 12 Weeks Results From a Surveillance, Epidemiology, and End Results-Medicare Analysis [J].
Gore, John L. ;
Lai, Julie ;
Setodji, Claude M. ;
Litwin, Mark S. ;
Saigal, Christopher S. .
CANCER, 2009, 115 (05) :988-996
[10]   International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial [J].
Griffiths, Gareth .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) :2171-2177